Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Oncology Biomarker Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Lung Cancer
  • 1.4.3 Breast Cancer
  • 1.4.4 Colorectal Cancer
  • 1.4.5 Prostate Cancer
  • 1.4.6 Stomach Cancer
  • 1.4.7 Others
• 1.5 Market by Application
  • 1.5.1 Global Oncology Biomarker Market Share by Application (2019-2025)
  • 1.5.2 Diagnostics
  • 1.5.3 Drug Discovery And Development
  • 1.5.4 Prognostics
  • 1.5.5 Risk Assessment
  • 1.5.6 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Oncology Biomarker Market Size
• 2.2 Oncology Biomarker Growth Trends by Regions
  • 2.2.1 Oncology Biomarker Market Size by Regions (2019-2025)
  • 2.2.2 Oncology Biomarker Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Oncology Biomarker Market Size by by Players
  • 3.1.1 Global Oncology Biomarker Revenue by by Players (2014-2019)
  • 3.1.2 Global Oncology Biomarker Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Oncology Biomarker Market Concentration Ratio (CR5 and HHI)
• 3.2 Oncology Biomarker Key Players Head office and Area Served
• 3.3 Key Players Oncology Biomarker Product/Solution/Service
• 3.4 Date of Enter into Oncology Biomarker Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Oncology Biomarker Market Size by Type (2014-2019)
• 4.2 Global Oncology Biomarker Market Size by Application (2014-2019)

5 North America

• 5.1 North America Oncology Biomarker Market Size (2014-2019)
• 5.2 Oncology Biomarker Key Players in North America
• 5.3 North America Oncology Biomarker Market Size by Type
• 5.4 North America Oncology Biomarker Market Size by Application

6 Europe

• 6.1 Europe Oncology Biomarker Market Size (2014-2019)
• 6.2 Oncology Biomarker Key Players in Europe
• 6.3 Europe Oncology Biomarker Market Size by Type
• 6.4 Europe Oncology Biomarker Market Size by Application

7 China

• 7.1 China Oncology Biomarker Market Size (2014-2019)
• 7.2 Oncology Biomarker Key Players in China
• 7.3 China Oncology Biomarker Market Size by Type
• 7.4 China Oncology Biomarker Market Size by Application

8 Japan

• 8.1 Japan Oncology Biomarker Market Size (2014-2019)
• 8.2 Oncology Biomarker Key Players in Japan
• 8.3 Japan Oncology Biomarker Market Size by Type
• 8.4 Japan Oncology Biomarker Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Oncology Biomarker Market Size (2014-2019)
• 9.2 Oncology Biomarker Key Players in Southeast Asia
• 9.3 Southeast Asia Oncology Biomarker Market Size by Type
• 9.4 Southeast Asia Oncology Biomarker Market Size by Application

10 India

• 10.1 India Oncology Biomarker Market Size (2014-2019)
• 10.2 Oncology Biomarker Key Players in India
• 10.3 India Oncology Biomarker Market Size by Type
• 10.4 India Oncology Biomarker Market Size by Application

11 Central & South America

• 11.1 Central & South America Oncology Biomarker Market Size (2014-2019)
• 11.2 Oncology Biomarker Key Players in Central & South America
• 11.3 Central & South America Oncology Biomarker Market Size by Type
• 11.4 Central & South America Oncology Biomarker Market Size by Application

12 International Players Profiles

• 12.1 Abbott Laboratories
  • 12.1.1 Abbott Laboratories Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Oncology Biomarker Introduction
  • 12.1.4 Abbott Laboratories Revenue in Oncology Biomarker Business (2014-2019))
  • 12.1.5 Abbott Laboratories Recent Development
• 12.2 Bristol-Myers Squibb
  • 12.2.1 Bristol-Myers Squibb Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Oncology Biomarker Introduction
  • 12.2.4 Bristol-Myers Squibb Revenue in Oncology Biomarker Business (2014-2019)
  • 12.2.5 Bristol-Myers Squibb Recent Development
• 12.3 Eli Lilly and Company
  • 12.3.1 Eli Lilly and Company Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Oncology Biomarker Introduction
  • 12.3.4 Eli Lilly and Company Revenue in Oncology Biomarker Business (2014-2019)
  • 12.3.5 Eli Lilly and Company Recent Development
• 12.4 F.Hoffmann-La Roche Ltd.
  • 12.4.1 F.Hoffmann-La Roche Ltd. Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Oncology Biomarker Introduction
  • 12.4.4 F.Hoffmann-La Roche Ltd. Revenue in Oncology Biomarker Business (2014-2019)
  • 12.4.5 F.Hoffmann-La Roche Ltd. Recent Development
• 12.5 Genomic Health
  • 12.5.1 Genomic Health Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Oncology Biomarker Introduction
  • 12.5.4 Genomic Health Revenue in Oncology Biomarker Business (2014-2019)
  • 12.5.5 Genomic Health Recent Development
• 12.6 GlaxoSmithKline plc
  • 12.6.1 GlaxoSmithKline plc Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Oncology Biomarker Introduction
  • 12.6.4 GlaxoSmithKline plc Revenue in Oncology Biomarker Business (2014-2019)
  • 12.6.5 GlaxoSmithKline plc Recent Development
• 12.7 Novartis AG
  • 12.7.1 Novartis AG Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Oncology Biomarker Introduction
  • 12.7.4 Novartis AG Revenue in Oncology Biomarker Business (2014-2019)
  • 12.7.5 Novartis AG Recent Development
• 12.8 Merck & Co.
  • 12.8.1 Merck & Co. Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Oncology Biomarker Introduction
  • 12.8.4 Merck & Co. Revenue in Oncology Biomarker Business (2014-2019)
  • 12.8.5 Merck & Co. Recent Development
• 12.9 Pfizer
  • 12.9.1 Pfizer Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Oncology Biomarker Introduction
  • 12.9.4 Pfizer Revenue in Oncology Biomarker Business (2014-2019)
  • 12.9.5 Pfizer Recent Development
• 12.10 Qiagen N.V.
  • 12.10.1 Qiagen N.V. Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Oncology Biomarker Introduction
  • 12.10.4 Qiagen N.V. Revenue in Oncology Biomarker Business (2014-2019)
  • 12.10.5 Qiagen N.V. Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Product (2019-2025)
• 13.2 Market Size Forecast by Application (2019-2025)
• 13.3 Market Size Forecast by Regions
• 13.4 North America
• 13.5 Europe
• 13.6 China
• 13.7 Japan
• 13.8 Southeast Asia
• 13.9 India
• 13.10 Central & South America

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer

A biomarker is referred to as a traceable biomolecule, whose presence found in body fluids such as blood, serum, urine, and tumor fluid that indicates disease or an underlying condition such as cancer.
In 2018, the global Oncology Biomarker market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Oncology Biomarker status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Oncology Biomarker development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Abbott Laboratories
Bristol-Myers Squibb
Eli Lilly and Company
F.Hoffmann-La Roche Ltd.
Genomic Health
GlaxoSmithKline plc
Novartis AG
Merck & Co.
Pfizer
Qiagen N.V.

Market segment by Type, the product can be split into
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Others

Market segment by Application, split into
Diagnostics
Drug Discovery And Development
Prognostics
Risk Assessment
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Oncology Biomarker status, future forecast, growth opportunity, key market and key players.
To present the Oncology Biomarker development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Oncology Biomarker are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.